Targeting ferroptosis protects against experimental (multi)organ dysfunction and deathSamya Van Coillie, Tom Vanden Berghe, Irina Ingold et al.|Nature Communications|2022Cited by 176
Ferroptosis contributes to multiple sclerosis and its pharmacological targeting suppresses experimental disease progressionEmily Van San, Tom Vanden Berghe, Angela C. Debruyne et al.|Cell Death and Differentiation|2023Cited by 93
Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver diseaseCédric Peleman, Tom Vanden Berghe, Stig Hellemans et al.|Cell Death and Differentiation|2024Cited by 36
Oxazole-Based Ferroptosis Inhibitors with Promising Properties to Treat Central Nervous System DiseasesCamilla Scarpellini, Koen Augustyns, Greta Klejborowska et al.|Journal of Medicinal Chemistry|2025Cited by 12
From PERK to RIPK1: Design, synthesis and evaluation of novel potent and selective necroptosis inhibitorsCamilla Scarpellini, Koen Augustyns|Frontiers in Chemistry|2023Cited by 3